Partner With Us NRI

Company details

6M Return -30.79%
1Y Return -37.96%
Mkt Cap.(Cr) 583.47
Volume 5,834
Div Yield 1.23%
OI Chg %
Volume 5,834

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 360.59 Cr FV: 5.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 25,587.81 -39,369.84
LAST 3M 74,012.99 -53,901.04
LAST 6M 141,118.09 -188,404.80
LAST 12M 210,989.03 -182,647.76


  • About Company
  • Company Info
  • Listing Info
  • Promoted by a technocrat, D V K Raju, Duphar-Interfran (DIL) was incorporated in May `51 as International Franchises Pvt Ltd. In the initial years, the company manufactured and sold toothpaste, anti-septic lotion and pharmaceutical specialities on a loan-licence basis. It entered into collaborations with Philips-Duphar, Amsterdam (Solvay Duphar), and the Crookes Laboratories, London. These collaborators participated in the equity capital of the company to the extent of 25% each. The company changed its name to Crookes Interfran on 19 Apr.`63. In 1964, it entered into a collaboration with Solvay Duphar to manufacture vitamin D3. To associate fully with its research-oriented collaborators, in May `71, it changed its name to Duphar-Interfran. In 1976, it entered into another collaboration with Solvay Duphar to manufacture isoxypurine hydrochloride -- a vasodilator. In 1976, in compliance with the FERA, the foreign collaborators reduced thier stake to 38.86%. DIL came out with a rights issue in May `95 to augment long-term resources and working capital requirements. The company also sold its popular analgesic brand Crocin to Smithkline Beecham Pharmaceuticals. It also sold another OTC brand, Lacto-Calamine lotion to Nicholas Piramal to concentrate on the core business of ethical drugs. As per the Scheme of Arrangement, the pharma business of the company has been transferred to a new company called Duphar Pharma India. The Company has made investments in unutilised premises at Thane to create a commercial complex with modern facilities so that substantial portion of it can be let out to earn income. The successful entry of Annual Contract with Solvay Pharmaceuticals B V of Netherlands will definitely establish as a reliable contract research organization for Duphar Interfran Ltd. As mutual consent with Solvay Pharmaceuticals,Netherlands,the company has been permitted to continue with the name DUPHAR for a limited time. It has also been decided to change the name to DIL Limited from Duphar-Interfran Ltd. With the prior approval from Board the company has acquired 990,000 equity shares of Rs.10 each in Fermenta Biotech Ltd there by increase its holding to 83.71% comprising 16,57,500 equity shares. Subsequent to this FBL will henceforth be a subsidiary of Duphar Interfran Ltd.

Read More

No Data Found

AGM Date (Month) : Oct
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 506414
NSE Code :
Book Closure Date (Month) :
BSE Group : X
ISIN : INE225B01021

ICICIdirect Fermenta Biotech Ltd FAQ

You can buy Fermenta Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Fermenta Biotech Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 26, 2022 04:01 PM the closing price of Fermenta Biotech Ltd was ₹ 198.25.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 26, 2022 04:01 PM, the market cap of Fermenta Biotech Ltd stood at ₹ 583.47.
The latest PE ratio of Fermenta Biotech Ltd as of May 26, 2022 04:01 PM is 38.58
The latest PB ratio of Fermenta Biotech Ltd as of May 26, 2022 04:01 PM is 0.64
The 52-week high of Fermenta Biotech Ltd is ₹ 370.00 while the 52-week low is ₹ 190.15 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote